About the Principal Investigator
Patrick W.B. Derksen, PhD (Oldenzaal, 23 May 1970)
+31 6 46240923 | +31 88 7568068 | p.w.b.derksen.AT.umcutrecht.nl | www.derksenlab.org
SUMMARY
Professor and Principal Investigator (PI) at the University Medical Center (UMC) Utrecht with an excellent track record in discovery and preclinical oncology. Specialist in conditional knockout mouse models, with a focus on loss of cell adhesion and tumor progression in breast cancer. International work experience and a strong international network builder in the academic field. Has generated high-impact publications in top scientific journals. Successful acquisition of external funding (approx.1M€/year). Trilingual business fluency in English, Dutch and German. Currently heading a Research lab with 15FTE scientific personnel. Initiator and head of the UMC Utrecht Mouse Cancer Clinic. Coordinator of the BSc Clinical Oncology course (Biomedical Sciences). Founder of the European Lobular Breast Cancer Consortium (24 Institutes, 50+ PI’s, 5 patient advocates, 13 countries) sponsored by COST (CA19138).
EDUCATION | TRAINING
1998-2003 PhD, Molecular Biology (Academic Medical Center/University of Amsterdam).
WORK EXPERIENCE
2021 - current Professor
2010 – 2021 Associate Professor
2007 – 2010 Assistant Professor
University Medical Center (UMC) Utrecht, The Netherlands. (Depts. of Pathology and Medical Oncology)
Main achievements: Formed, expanded and consolidated successful lines of research.
Earned international recognition.
Received personal NWO-VIDI grant.
2003 – 2007 Post-Doctoral Fellow
Netherlands Cancer Institute, Amsterdam, The Netherlands. (Division of Molecular Biology)
Main achievements: Published in the top Cancer Journal (Cancer Cell).
Received personal NWO-VENI award.
LEADERSHIP EXPERIENCE
- Supervised 20 PhD-track graduate and >20 undergraduate (MSc/BSc) students.
- Heading an independent research group of 14 externally-funded researchers.
- Founder of the European Lobular Breast Cancer Consortium (ELBCC).
- Board Member of the Cancer Research UK New Investigator Panel.
- Member of the Science Board UMC Utrecht (Division Laboratories and Biomedical Genetics).
INTERNATIONAL ACTIVITIES
- Actively collaborating with 15 International peers
- More than 20 Seminars as Invited Speaker
- Research Sabbatical (2013-2014). Salk Institute for Biological Sciences, La Jolla, CA
- BSc Internship BSc internship (1997), University of Warwick, Coventry, UK
- Member of:
European Network of Breast Development and Cancer Labs.
American Association for Cancer Research, American Society of Cell Biology.
TEACHING ACTIVITIES
- Course coordinator Clinical Oncology (Bachelor’s phase Biomedical Sciences, Utrecht University)
- Lecturer Molecular Pathology (Bachelor’s phase Biomedical Sciences, Utrecht University)
- Lecturer Cell Adhesion in Health and Disease (Bachelor’s phase Leiden University)
- Course Coordinator and co-organiser ‘Breast and Colon Cancer’
(Graduate school Clinical and Translational Oncology, UMC Utrecht)
- Lecturer Mouse Transgenic models (Graduate School Regenerative Medicine, UMC Utrecht)
HONORS AND AWARDS
- NWO-VENI (916.56.135. 2005)
- NWO-VIDI (016.096.318. 2008)
- Pink Ribbon Award 2008
- Vice-Chair/Chair, Gordon Research Conferences (Signaling by Adhesion Receptors), 2020/2022.
BIBLIOGRAPHIC DATA
- Number of publications: (53)
- First author (7)
- Contributing author (24)
- Senior author (22)
- h-index (31)
- My average impact facto (8.4)
TOP 5 PUBLICATIONS
1. Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.
Cancer Discov. 2018 Apr;8(4).
2. van de Ven RAH, de Groot J, Park D, van Domselaar R, de Jong D, Szuhai K, van der Wall E, Rueda OM, Ali HR, Caldas C, van Diest PJ, Hetzer MW, Sahai E, Derksen PW. p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis.
Nat Commun. 2016 Dec 22;7:13874.
3. Bouchet BP, Noordstra I, van Amersfoort M, ter Hoeve ND, Hodgson L, Dogterom M, Derksen PW, Akhmanova A. Microtubule growth persistence controls mesenchymal cell migration in 3D matrix and tumor invasion.
Dev Cell. 2016 19;39(6):708-723.
4. Schackmann RCJ, van Amersfoort M, Haarhuis JHI, Vlug EJ, Halim VA, Roodhart JML, Vermaat JS, Voest EE, van der Groep P, Van Diest PJ, Jonkers J, Derksen PW. Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.
J Clin Invest. 2011 Aug;121(8):3176–88.
5. Derksen PW, Liu X, Saridin F, Van Der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.
Cancer Cell. 2006 Nov;10(5):437–49.
Patrick W.B. Derksen, PhD (Oldenzaal, 23 May 1970)
+31 6 46240923 | +31 88 7568068 | p.w.b.derksen.AT.umcutrecht.nl | www.derksenlab.org
SUMMARY
Professor and Principal Investigator (PI) at the University Medical Center (UMC) Utrecht with an excellent track record in discovery and preclinical oncology. Specialist in conditional knockout mouse models, with a focus on loss of cell adhesion and tumor progression in breast cancer. International work experience and a strong international network builder in the academic field. Has generated high-impact publications in top scientific journals. Successful acquisition of external funding (approx.1M€/year). Trilingual business fluency in English, Dutch and German. Currently heading a Research lab with 15FTE scientific personnel. Initiator and head of the UMC Utrecht Mouse Cancer Clinic. Coordinator of the BSc Clinical Oncology course (Biomedical Sciences). Founder of the European Lobular Breast Cancer Consortium (24 Institutes, 50+ PI’s, 5 patient advocates, 13 countries) sponsored by COST (CA19138).
EDUCATION | TRAINING
1998-2003 PhD, Molecular Biology (Academic Medical Center/University of Amsterdam).
WORK EXPERIENCE
2021 - current Professor
2010 – 2021 Associate Professor
2007 – 2010 Assistant Professor
University Medical Center (UMC) Utrecht, The Netherlands. (Depts. of Pathology and Medical Oncology)
Main achievements: Formed, expanded and consolidated successful lines of research.
Earned international recognition.
Received personal NWO-VIDI grant.
2003 – 2007 Post-Doctoral Fellow
Netherlands Cancer Institute, Amsterdam, The Netherlands. (Division of Molecular Biology)
Main achievements: Published in the top Cancer Journal (Cancer Cell).
Received personal NWO-VENI award.
LEADERSHIP EXPERIENCE
- Supervised 20 PhD-track graduate and >20 undergraduate (MSc/BSc) students.
- Heading an independent research group of 14 externally-funded researchers.
- Founder of the European Lobular Breast Cancer Consortium (ELBCC).
- Board Member of the Cancer Research UK New Investigator Panel.
- Member of the Science Board UMC Utrecht (Division Laboratories and Biomedical Genetics).
INTERNATIONAL ACTIVITIES
- Actively collaborating with 15 International peers
- More than 20 Seminars as Invited Speaker
- Research Sabbatical (2013-2014). Salk Institute for Biological Sciences, La Jolla, CA
- BSc Internship BSc internship (1997), University of Warwick, Coventry, UK
- Member of:
European Network of Breast Development and Cancer Labs.
American Association for Cancer Research, American Society of Cell Biology.
TEACHING ACTIVITIES
- Course coordinator Clinical Oncology (Bachelor’s phase Biomedical Sciences, Utrecht University)
- Lecturer Molecular Pathology (Bachelor’s phase Biomedical Sciences, Utrecht University)
- Lecturer Cell Adhesion in Health and Disease (Bachelor’s phase Leiden University)
- Course Coordinator and co-organiser ‘Breast and Colon Cancer’
(Graduate school Clinical and Translational Oncology, UMC Utrecht)
- Lecturer Mouse Transgenic models (Graduate School Regenerative Medicine, UMC Utrecht)
HONORS AND AWARDS
- NWO-VENI (916.56.135. 2005)
- NWO-VIDI (016.096.318. 2008)
- Pink Ribbon Award 2008
- Vice-Chair/Chair, Gordon Research Conferences (Signaling by Adhesion Receptors), 2020/2022.
BIBLIOGRAPHIC DATA
- Number of publications: (53)
- First author (7)
- Contributing author (24)
- Senior author (22)
- h-index (31)
- My average impact facto (8.4)
TOP 5 PUBLICATIONS
1. Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.
Cancer Discov. 2018 Apr;8(4).
2. van de Ven RAH, de Groot J, Park D, van Domselaar R, de Jong D, Szuhai K, van der Wall E, Rueda OM, Ali HR, Caldas C, van Diest PJ, Hetzer MW, Sahai E, Derksen PW. p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesis.
Nat Commun. 2016 Dec 22;7:13874.
3. Bouchet BP, Noordstra I, van Amersfoort M, ter Hoeve ND, Hodgson L, Dogterom M, Derksen PW, Akhmanova A. Microtubule growth persistence controls mesenchymal cell migration in 3D matrix and tumor invasion.
Dev Cell. 2016 19;39(6):708-723.
4. Schackmann RCJ, van Amersfoort M, Haarhuis JHI, Vlug EJ, Halim VA, Roodhart JML, Vermaat JS, Voest EE, van der Groep P, Van Diest PJ, Jonkers J, Derksen PW. Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.
J Clin Invest. 2011 Aug;121(8):3176–88.
5. Derksen PW, Liu X, Saridin F, Van Der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.
Cancer Cell. 2006 Nov;10(5):437–49.
